FORT LAUDERDALE, Fla., Dec. 14, 2017 -- TFS International, a global clinical contract research organization (TFS), has signed a new three-year partnership agreement with OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology. Under the agreement, TFS will use OmniComm’s TrialMaster EDC technology to develop clinical studies in multiple TFS research sites around the world.
“Our main technology partner over recent years has been OmniComm, and we are thrilled to continue to develop studies with the TrialMaster platform with innovations such as the Protocol Deviation Module, which was recently designed at TFS. Our collaborative technological advances will assist with the management of our clinical trials and ensure new medicines are brought to market for patients,” said Ed Tumaian, vice president, Global Clinical Development at TFS International.
The strong long-term relationship between the two companies and OmniComm’s extensive knowledge of the electronic data capture (EDC) products and services that are best-suited for TFS drove the decision to sign a new agreement, according to the TFS leadership team.
Other factors include:
- Successful development of efficiencies during the database setup phase of clinical studies.
- OmniComm’s ability to personalize the EDC environment for TFS customers (e.g. tailored roles and work flows within TrialMaster, ad-hoc reports and real-time connection with other vendors).
- Excellent customer service from OmniComm’s technical support team.
Since 2014, TFS has used OmniComm’s EDC technology for an increasing number of concurrent studies, involving more than 1,000 sites and 5,000 patients.
“We take great pride in our ongoing partnership with TFS International, and we are delighted TFS has chosen to continue using TrialMaster as one of its strategic EDC solutions,” said Yvonne Rollinger, Ph.D., managing director of OmniComm Europe GmbH. “To have an organization as prestigious as TFS International select TrialMaster is a testament to the quality, flexibility and scalability of both our EDC technology and our business operations.”
About TFS International
TFS International is the leading, mid-size clinical contract research organization (CRO) providing global clinical development solutions. Founded in 1996 in Sweden, TFS currently operates in over 25 countries throughout Europe and North America and employs more than 800 professionals. TFS’ core therapeutic areas of expertise are oncology, immunology, dermatology, ophthalmology and CNS. Through two business areas, TFS Develop™ and TFS People™, TFS provides services worldwide as end-to-end solutions or tactical functional services. Please visit www.tfscro.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 5,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster, TrialOne and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
[email protected]


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
Instagram Outage Disrupts Thousands of U.S. Users
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 



